Desvenlafaxine
- Generic Name
- Desvenlafaxine
- Brand Names
- Pristiq
- Drug Type
- Small Molecule
- Chemical Formula
- C16H25NO2
- CAS Number
- 93413-62-8
- Unique Ingredient Identifier
- NG99554ANW
- Background
Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of venlafaxine. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class. It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).
...
- Indication
Desvenlafaxine is indicated for the treatment of major depressive disorder in adults. It has also been used off-label to treat hot flashes in menopausal women.
- Associated Conditions
- Hot Flashes, Major Depressive Disorder (MDD)
- Associated Therapies
- -
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- Conditions
- Interventions
- Drug: FezolinetantDrug: ParoxetineDrug: GabapentinDrug: CitalopramDrug: ClonidineDrug: PregabalinDrug: EscitalopramDrug: DesvenlafaxineDrug: OxybutyninDrug: Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category aboveDrug: VenlafaxineDrug: Any other SSRI/SNRI not already specified
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT06049797
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸SUNY Downstate Health Sciences University, Brooklyn, New York, United States
🇺🇸Mohawk Valley Health System - Womens Health Center, Utica, New York, United States
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 440
- Registration Number
- NCT04476030
- Locations
- 🇺🇸
Sage Investigational Site, Bellevue, Washington, United States
Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression
- Conditions
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 605
- Registration Number
- NCT04448431
- Locations
- 🇦🇷
INAPsi (Instituto Nacional de Psicopatologia), Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
🇲🇽CRI Centro Regiomontano de Investigacion SC, Monterrey, Nuevo Leon, Mexico
🇷🇺Leningrad Regional Psychoneurological Dispensary, Roshchino, Leningrad Region, Russian Federation
Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 370212
- Registration Number
- NCT04446039
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
A Study of LY03005 vs Pristiq
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT03733574
- Locations
- 🇺🇸
Pharmaron CPC, Inc., Baltimore, Maryland, United States
Switching From SSRI to Desvenlafaxine on Cognitive Functioning
- Conditions
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- Corporacion Parc Tauli
- Target Recruit Count
- 36
- Registration Number
- NCT03432221
- Locations
- 🇪🇸
Corporació Sanitària Parc Taulí, Sabadell, Spain
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03357796
- Locations
- 🇺🇸
Clinilabs, Inc., Eatontown, New Jersey, United States
Pilot BA Study of New LY03005 vs Pristiq
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02988024
- Locations
- 🇺🇸
Clinilabs, Inc., Eatontown, New Jersey, United States
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Conditions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 1037352
- Registration Number
- NCT02893371
- Locations
- 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States
Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 56
- Registration Number
- NCT02859103
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.